Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam-Reference-Cited by-同舟云学术

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sime Fekade B.¹,Pandey Saurabh²,Karamujic Nermin²,Parker Suzanne²,Alexander Elizabeth³,Loutit Jeffery³,Durso Stephanie³,Griffith David³,Lipman Jeffrey²⁴,Wallis Steven C.²,Roberts Jason A.¹²⁴⁵^ORCID

Affiliation:

1. School of Pharmacy, Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia

2. University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia

3. The Medicines Company, San Diego, California, USA

4. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia

5. Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia

Abstract

The combination product meropenem-vaborbactam, with activity against KPC-producing carbapenem-resistant Enterobacteriaceae , is likely to be used during renal replacement therapy. The aim of this work was to describe the extracorporeal removal (adsorption and clearance) of meropenem-vaborbactam during continuous venovenous hemofiltration (CVVH).

Funder

The Medicines Company

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01306-18

Reference32 articles.

1. WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 11 March 2018.

2. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

3. Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates;Ye Y;Exp Ther Med,2018

4. FDA. 29 August 2017. FDA approves new antibacterial drug. FDA, Washington, DC. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm. Accessed 11 March 2018.

5. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication patterns and dosing guidance in pediatric patients supported with intermittent hemodialysis or continuous kidney replacement therapy;Pediatric Nephrology;2023-12-05

2. Meropenem Clearance in a Child With End-stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy: A Case Report and Literature Review;Pediatric Infectious Disease Journal;2023-09-12

3. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF);Journal of Critical Care;2023-08

4. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients;Annals of Intensive Care;2023-07-18

5. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams;Expert Review of Anti-infective Therapy;2023-01-31